Literature DB >> 24255893

Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.

Hernán Trimarchi1.   

Abstract

Primary focal and segmental glomerulosclerosis (FSGS) may be due to genetic or acquired etiologies and is a common cause of nephrotic syndrome with high morbidity that often leads to end-stage renal failure. The different available therapeutic approaches are unsuccessful, in part due to partially deciphered heterogeneous and complex pathophysiological mechanisms. Moreover, the term FSGS, even in its primary form, comprises a histological description shared by a number of different causes with completely different molecular pathways of disease. This review focuses on the latest developments regarding the pathophysiology of primary acquired FSGS caused by soluble factor urokinase type plasminogen activator receptor, a circulating permeability factor involved in proteinuria and edema formation, and describes recent advances with potential success in therapy.

Entities:  

Keywords:  Plasmin; Podocyte; Primary acquired focal and segmental glomerulosclerosis; Proteinuria; Soluble factor urokinase type plasminogen activator receptor

Year:  2013        PMID: 24255893      PMCID: PMC3832866          DOI: 10.5527/wjn.v2.i4.103

Source DB:  PubMed          Journal:  World J Nephrol        ISSN: 2220-6124


  74 in total

1.  Treatment of primary focal segmental glomerulosclerosis.

Authors:  Stephen M Korbet
Journal:  Kidney Int       Date:  2002-12       Impact factor: 10.612

Review 2.  Therapeutic apheresis rescue mission: recurrent focal segmental glomerulosclerosis in renal allografts.

Authors:  Douglas Scott Keith
Journal:  Semin Dial       Date:  2011-12-16       Impact factor: 3.455

3.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  suPAR and FSGS: the gap between bench and bedside.

Authors:  Maarten Naesens; Björn Meijers; Ben Sprangers
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

5.  Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.

Authors:  Kandai Nozu; Kazumoto Iijima; Masato Fujisawa; Atsuko Nakagawa; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

6.  Focal and segmental glomerulosclerosis in children: a longitudinal assessment.

Authors:  Olivia Boyer; Janelle K Moulder; Michael J G Somers
Journal:  Pediatr Nephrol       Date:  2007-04-17       Impact factor: 3.714

Review 7.  Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Ellen T McCarthy; Mukut Sharma; Virginia J Savin
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-21       Impact factor: 8.237

8.  Recurrence of proteinuria following renal transplantation in congenital nephrotic syndrome of the Finnish type.

Authors:  Tarak Srivastava; Robert E Garola; Marjo Kestila; Karl Tryggvason; Vesa Ruotsalainen; Mukut Sharma; Virginia J Savin; Hannu Jalanko; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2006-03-04       Impact factor: 3.714

9.  Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy.

Authors:  Laura Barisoni; H William Schnaper; Jeffrey B Kopp
Journal:  Arch Pathol Lab Med       Date:  2009-02       Impact factor: 5.534

10.  Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo.

Authors:  A E May; S M Kanse; L R Lund; R H Gisler; B A Imhof; K T Preissner
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  12 in total

Review 1.  Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Pediatr Nephrol       Date:  2015-05-05       Impact factor: 3.714

2.  Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.

Authors:  Claudio Musetti; Marco Quaglia; Tiziana Cena; Annalisa Chiocchetti; Sara Monti; Nausicaa Clemente; Corrado Magnani; Umberto Dianzani; Piero Stratta
Journal:  J Nephrol       Date:  2014-09-04       Impact factor: 3.902

Review 3.  New therapeutic perspectives for IgA nephropathy in children.

Authors:  Alexandra Cambier; Patrick J Gleeson; Héloise Flament; Marie-Bénédicte Le Stang; Renato C Monteiro
Journal:  Pediatr Nephrol       Date:  2020-02-10       Impact factor: 3.714

Review 4.  Mechanisms of Podocyte Detachment, Podocyturia, and Risk of Progression of Glomerulopathies.

Authors:  Hernán Trimarchi
Journal:  Kidney Dis (Basel)       Date:  2020-05-27

5.  Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease.

Authors:  H Trimarchi; R Canzonieri; A Muryan; A Schiel; A Araoz; M Forrester; A Karl; F Lombi; J Andrews; V Pomeranz; T Rengel; E Zotta
Journal:  Case Rep Nephrol       Date:  2015-05-21

6.  Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR.

Authors:  H Trimarchi; M Forrester; F Lombi; V Pomeranz; M S Raña; A Karl; J Andrews
Journal:  Case Rep Nephrol       Date:  2014-05-15

7.  A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.

Authors:  Joann M Spinale; Laura H Mariani; Shiv Kapoor; Jidong Zhang; Robert Weyant; Peter X Song; Hetty N Wong; Jonathan P Troost; Crystal A Gadegbeku; Debbie S Gipson; Matthias Kretzler; Deepak Nihalani; Lawrence B Holzman
Journal:  Kidney Int       Date:  2014-10-29       Impact factor: 10.612

Review 8.  Podocyturia: What is in a name?

Authors:  Hernán Trimarchi
Journal:  J Transl Int Med       Date:  2015-06-30

Review 9.  Roles of Immune Cells in Hereditary Angioedema.

Authors:  Anne Lise Ferrara; Leonardo Cristinziano; Angelica Petraroli; Maria Bova; Maria Celeste Gigliotti; Simone Marcella; Luca Modestino; Gilda Varricchi; Mariantonia Braile; Maria Rosaria Galdiero; Giuseppe Spadaro; Stefania Loffredo
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-29       Impact factor: 8.667

10.  Urokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy.

Authors:  Cheng-Hsu Chen; Shih-Yin Chen; Kuo-Hsiung Shu; Mei-Chin Wen; Chi-Hung Cheng; Ming-Ju Wu; Tung-Min Yu; Ya-Wen Chuang; Fuu-Jen Tsai
Journal:  Biomed Res Int       Date:  2014-04-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.